




Form PT-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket No:		Application No:			
		18085.105093 (EMU120CON)		09/879,854			
		Applicant:					
		Raymond F. Schinazi, <i>et al.</i>					
		Filing Date:		Group Art Unit:			
		June 12, 2001		1614			
U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Name	U.S. Class	U.S. Subclass	Filing Date If Appropriate
1	AA	4,000,137	12/28/76	Dvorch, <i>et al.</i>	260	252	06/10/75
	AB	4,140,761	02/20/79	Gerin, <i>et al.</i>	424	85	04/11/77
	AC	4,336,381	06/22/82	Nagata, <i>et al.</i>	544	313	11/03/80
	AD	4,788,181	11/29/88	Driscoll <i>et al.</i>	514	49	09/29/86
	AE	4,818,538	04/04/89	Rideout, <i>et al.</i>	424	436	10/21/87
	AF	4,861,759	08/29/89	Mitsuya, <i>et al.</i>	514	46	08/11/87
	AG	4,879,277	11/07/89	Mitsuya, <i>et al.</i>	514	49	08/11/87
	AH	4,900,828	02/13/90	Belica, <i>et al.</i>	544	317	05/12/88
	AI	4,916,122	04/10/90	Chu, <i>et al.</i>	514	50	10/02/87
	AJ	4,963,533	10/16/90	de Clercq, <i>et al.</i>	514	49	10/24/86
	AK	5,041,449	08/20/91	Belleau, <i>et al.</i>	514	274	06/29/90
	AL	5,047,407	09/10/91	Belleau, <i>et al.</i>	514	274	02/08/89
	AM	5,059,690	10/22/91	Zahler, <i>et al.</i>	544	276	05/01/90
	AN	5,089,500	02/18/92	Daluge	514	261	05/08/91
	AO	5,149,794	09/22/92	Yatvin, <i>et al.</i>	536	29	11/01/90
	AP	5,151,426	09/29/92	Belleau, <i>et al.</i>	514	262	06/17/91
	AQ	5,179,104	01/12/93	Chu, <i>et al.</i>	544	310	12/05/90
	AR	5,185,437	02/09/93	Koszalka, <i>et al.</i>	536	24	08/31/91
	AS	5,194,654	03/16/93	Hostetler, <i>et al.</i>	558	152	11/22/89
	AT	5,204,466	04/20/93	Liotta, <i>et al.</i>	544	317	02/01/90
	AU	5,210,085	05/11/93	Liotta, <i>et al.</i>	514	274	02/22/91
AV	5,223,263	06/29/93	Hostetler, <i>et al.</i>	424	450	06/28/89	
AW	5,234,913	08/10/93	Furman, Jr. <i>et al.</i>	514	49	03/05/92	
AX	5,248,776	09/28/93	Chu, <i>et al.</i>	544	310	12/05/91	
AY	5,256,641	10/26/93	Yatvin, <i>et al.</i>	514	2	07/09/92	
AZ	5,270,315	12/14/93	Belleau, <i>et al.</i>	514	262	03/07/91	
AAA	5,276,151	01/04/94	Liotta	544	317	12/06/91	
AAB	5,411,947	05/02/95	Hostetler, <i>et al.</i>	514	43	12/06/92	
AAC	5,444,063	08/22/95	Schinazi	514	262	10/28/92	
AAD	5,463,092	10/31/95	Hostetler, <i>et al.</i>	554	40	12/18/92	
AAE	5,466,806	11/14/95	Belleau, <i>et al.</i>	544	310	03/29/93	
AAF	5,486,520	01/23/96	Belleau, <i>et al.</i>	514	274	12/10/93	
AAG	5,532,246	07/02/96	Belleau, <i>et al.</i>	514	274	01/03/92	
AAH	5,539,116	07/23/96	Liotta, <i>et al.</i>	544	317	02/10/93	
AAI	5,543,389	08/06/96	Yatvin, <i>et al.</i>	514	2	10/26/93	
Examiner:			Date Considered: 11/20/06				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							




Form PTO-1449		Docket No:		Application No.			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		18085.105093 (EMU120CON)		09/879,854			
		Applicant:					
		Raymond F. Schinazi, et al.					
		Filing Date:		Group Art Unit			
		June 12, 2001		1614			
U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Name	U.S. Class	U.S. Subclass	Filing Date if Appropriate
[Signature]	BA	5,543,390	08/06/96	Yatvin, et al.	514	2	05/19/94
	BB	5,543,391	08/06/96	Yatvin, et al.	514	2	05/16/95
	BC	5,554,728	09/10/96	Basava, et al.	530	327	07/23/95
	BD	5,561,120	10/01/96	Lin et al.	514	49	10/01/96
	BE	5,587,480	12/24/96	Belleau, et al.	544	310	04/20/94
	BF	5,604,209	02/18/97	Ubasawa et al.	514	45	06/02/94
	BG	5,627,160	05/06/97	Lin et al.	514	49	07/28/93
	BH	5,631,239	05/20/97	Lin et al.	514	49	10/18/95
	BI	5,696,254	12/09/97	Mansour et al.	536	27.11	05/21/92
	BJ	5,744,596	04/28/98	Mansour et al.	536	27.11	06/05/95
	BK	5,756,706	05/26/98	Mansour et al.	536	27.11	05/20/92
	BL	5,770,713	06/23/98	Imbach, et al.	536	22.1	05/11/94
	BM	5,770,725	06/23/98	Gosselin, et al.	536	26.7	04/04/95
	BN	5,849,905	12/15/98	Gosselin, et al.	536	26.7	09/13/96
	BO	5,852,027	12/22/98	Liotta et al.	514	274	02/21/92
	BP	5,990,093	11/23/99	Schinazi et al.	514	47	03/31/97
	BQ	6,156,737	12/05/00	Mansour et al.	514	49	12/22/93
	BR	6,245,749 B1	06/12/01	Schinazi et al.	514	47	06/09/98
FOREIGN PATENT DOCUMENTS							
Examiner Initials		Publication Number	Date	Country	Int. Cl. Patent	International Class Codes	
[Signature]	BS	0 217 580	A2	04/08/87	Europe	4	C 07 H 19/073
	BT	0 337 713	B1	10/18/89	Europe	6	C 07 D 473/32
	BU	0 350 287	A2	01/10/90	Europe	5	C 07 H 19/073
	BV	0 352 248	A1	01/24/90	Europe	5	C 07 H 19/06
	BW	0 375 329	A2	06/27/90	Europe	5	C 07 D 474/00
	BX	0 382 526	A2	08/16/90	Europe	5	C 07 D 473/00
	BY	0 433 898	A2	12/29/89	Europe	5	C 07 D 433/898
	BZ	0 494 119	A1	08/07/92	Europe	5	A 6K 31/505
	BBA	0 515 144	A1	11/25/92	Europe	6	A 61 K 31/505
BBB	0 515 156	A1	11/25/92	Europe	5	C 07 H 19/04	
Examiner: [Signature]				Date Considered: 1/20/06			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							




Form PTO-1449		Docket No:		Application No.		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		18085.105093 (EMU120CON)		09/879,854		
		Applicant:				
		Raymond F. Schinazi, et al.				
		Filing Date:		Group Art Unit		
		June 12, 2001		1614		
FOREIGN PATENT DOCUMENTS						
Examiner Initials		Publication Number	Date	Country	Int. Cl. Patent	International Class Codes
②	CA	0 515 157	A1	11/25/92	Europe	5 C 07 D 327/04
	CB	0 526 253	A1	02/03/93	Europe	5 C 07 D 411/04
	CC	WO 88/07532	A1	10/06/88	PCT	4 C 07 D 405/04
	CD	WO 88/08001	A1	10/20/88	PCT	4 C 07 H 19/06
	CE	WO 89/02733	A1	04/06/89	PCT	4 A 61 K 9/66
	CF	WO 90/00555	A1	01/25/90	PCT	4 C 07 H 15/12
	CG	WO 90/12023	A1	10/18/90	PCT	5 C 07 H 19/10
	CH	WO 91/11186	A1	08/08/91	PCT	5 A 61 K 31/505
	CI	WO 91/16920	A1	11/14/91	PCT	5 A 61 K 37/22
	CJ	WO 91/17159	A1	11/14/91	PCT	5 C 07 D 411/04
	CK	WO 91/18914	A1	12/12/91	PCT	5 C 07 H 17/00
	CL	WO 91/19721	A1	12/26/91	PCT	5 C 07 F 9/6558
	CM	WO 92/00315	A1	01/09/92	PCT	5 C 07 H 21/00
	CN	WO 92/06102	A1	04/16/92	PCT	5 C 07 H 19/06
	CO	WO 92/08717	A1	05/29/92	PCT	5 C 07 D 409/04
	CP	WO 92/10496	A1	06/25/92	PCT	5 C 07 D 475/00
	CQ	WO 92/10497	A1	06/25/92	PCT	5 C 07 D 475/00
	CR	WO 92/14729	A1	09/03/92	PCT	5 C 07 D 411/04
	CS	WO 92/14743	A2	09/03/92	PCT	5 C 07 H
	CT	WO 92/15308	A1	09/17/92	PCT	5 C 07 K 31/505
	CU	WO 92/18517	A1	10/29/92	PCT	5 C 07 D 17/00
	CV	WO 92/21676	A1	12/10/92	PCT	5 C 07 K 411/04
	CW	WO 93/00910	A1	01/21/93	PCT	5 A 61 K 31/70
	CX	WO 93/12128	A1	06/24/93	PCT	5 C 07 H 19/06
	CY	WO 93/12131	A1	06/24/93	PCT	5 C 07 H 21/00
	CZ	WO 93/12132	A1	06/24/93	PCT	5 C 07 H 21/00
	CCA	WO 93/24510	A1	12/09/93	PCT	5 C 07 H 19/70
	CCB	WO 94/04154	A1	03/03/94	PCT	5 A 61 K 3152
	CCC	WO 94/05300	A1	03/17/94	PCT	5 A 61 K 31/71
	CCD	WO 94/09793	A1	05/11/94	PCT	5 A 61 K 31/70
	CCE	WO 94/14456	A1	07/07/94	PCT	5 A 61 K 31/70
Examiner:	Date Considered:			1/26/06		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						




Form PTO-1449		Docket No:		Application No.				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		18085.105093 (EMU120CON)		09/879,854				
		Applicant:						
		Raymond F. Schinazi, <i>et al.</i>						
		Filing Date:		Group Art Unit				
		June 12, 2001		1614				
FOREIGN PATENT DOCUMENTS								
Examiner Initials		Publication Number		Date	Country	Int. Cl Patent	International Class Codes	
(72)	DA	WO 94/14802	A1	07/07/94	PCT	5	C 07 D	411/04
	DB	WO 94/26273	A1	11/24/94	PCT	5	A 61 K	31/44
	DC	WO 94/26764	A1	11/24/94	PCT	5	C 07 H	21/00
	DD	WO 94/27616	A1	12/08/94	PCT	5	A 61 K	31/70
	DE	WO 95/07287	A1	03/16/95	PCT	6	C 07 H	19/04
	DF	WO 95/11252	A1	04/27/95	PCT	6	C 07 H	19/10
	DG	WO 96/15132	A1	05/23/96	PCT	6	C 07 F	9/02
	DH	WO 95/20595	A1	08/03/95	PCT	6	C 07 H	19/00
	DI	WO 96/401164	A1	12-19-91	PCT	6	A 61 K	31/70
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	DJ	Ayoola, <i>et al.</i> , "Progress in the Control of Viral Hepatitis: Memorandum from a WHO Meeting," Bulletin of the World Health Organization, 66(4):443-455 (1988).						
	DK	Beach, <i>et al.</i> , "Synthesis of Enantiomerically Pure (2'R,5'S)-(-)-1-[2-(hydroxymethyl) oathiolan-5-yl]Cytosine as a Potential Antiviral Agent Against Hepatitis B (HBV) and Human Immunodeficiency," J. Org. Chem. 57:2217-2219 (1992).						
	DL	Beasley, <i>et al.</i> , "Hepatocellular Carcinoma and Hepatitis B Virus," <u>The Lancet</u> , 1129-1133 (1981).						
	DM	Belleau, B., <i>et al.</i> , "Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1...", <u>Intl. Conf. on AIDS</u> , Montreal, Quebec, Canada, June 4-9, 1989.						
	DN	Boutelje, <i>et al.</i> , <u>Chemical Abstracts</u> 108:128048 (1987).						
	DO	Chang, C-N., <i>et al.</i> , "Biochemical Pharmacology of (+) and (-)-2',3'-Dideoxy-3'-Thiacytidine as Anti-Hepatitis B Virus Agents," <u>J. Biol. Chem.</u> 267(31):22414-22420 (1992).						
	DP	Chang, Chien-Neng, <i>et al.</i> , "Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (+)-2'-3'-Dideoxy S'-Thiacytidine in the Inhibition of Hepatitis B Virus Replication," <u>J. Bio. Chem.</u> , 267(20):13938-13942 (1992).						
	DQ	Chang, Chungming, <i>et al.</i> , "Production of Hepatitis B Virus <i>in vitro</i> by Transient Expression of cloned HBV PNA in Hepatoma Cell Line," <u>The EMBO J.</u> 6(3):675-680 (1987).						
Examiner:		Date Considered: 1/20/06						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								




Form PTO-1449		Docket No:	Application No.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		18085.105093 (EMU120CON)	09/879,854
		Applicant:	
		Raymond F. Schinazi, <i>et al.</i>	
		Filing Date:	Group/Art Unit
		June 12, 2001	1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	EA	Chu, <i>et al.</i> , "Structure Activity Relationships of Pyrimiding Nucleosides as Antiviral Agents for Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells." <i>J. Med. Chem.</i> , 32:3 pp. 612-617 (1989).	
	EB	Chu, <i>et al.</i> , "Enantiomeric Synthesis of (+)-BCH-189[(+)-(2S,5R)-1-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine] from D-Mannose and Its Anti-HIV Activity," <i>J. Org. Chem.</i> , 56:6503-6505 (1991).	
	EC	Chu, <i>et al.</i> , "An Efficient Total Synthesis of 3'-Azido-3'-Deoxythymidine (AZT) and 3'-Azido-2',3'-Dideoxyuridine (AZDDU, CS-87) from D-Mannitol," <i>Tetrahedron Letters</i> , 29(42):5349-5352 (1988).	
	ED	Chu, <i>et al.</i> , "Comparative Activity of 2',3'-Saturated and Unsaturated Pyrimidine and Purine Nucleosides Against Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells," <i>Biochem. Pharm.</i> 37(19); pp. 3543-3548 (1988).	
	EE	Chu, <i>et al.</i> , "Synthesis and Biological Evaluation of D-(2S) and L-(2R)-1,3-Oxathiolanyl-and D-(2R)- and L-(2S)-1,3-Dioxolanyl-Nucleosides as Anti-HIV and Anti-HBV Agents," <i>Antiviral Research</i> , 30(S1):192; p. 146 (1993).	
	EF	Chu, <i>et al.</i> , "Synthesis and Anti-HIV and Anti-HBV Activity of Enantiomerically Pure Oxathiolane Nucleosides," <i>Antiviral Research</i> , 17(S1):2; p. 44 (1992).	
	EG	Chu, <i>et al.</i> , "Asymmetric Synthesis of Enantiomerically Pure (-)-(1'R,4'R)-Dioxolane-thymine and Its Anti-HIV Activity," <i>Tetrahedron Letters</i> , 32(31):3791-3794 (1991)	
	EH	Coates, <i>et al.</i> , "The Separated Enantiomers of 2'-Deoxy-3'-Thiacytidine (BCH-189) Both Inhibit Human Immunodeficiency Virus Replication In Vitro," <i>Antimicrob. Agents Chemother.</i> 36(1):202-205 (1992)	
	EI	Cretton, <i>et al.</i> , "Catabolism of 3'-Azido-3'-Deoxythymidine in Hepatocytes and Liver Microsomes, with Evidence of Formation of 3'-Amino-3'-Deoxythymidine a Highly Toxic Catabolite for Human Bone Marrow Cells," <i>Molecular Pharmacology</i> , 39:258-266 (1991).	
	EJ	Cretton, <i>et al.</i> , "Pharmokinetics of 3'-Azido-3'-Deoxythymidine and its Catabolites and Interactions with Probenecid in Rhesus Monkeys," <i>Antimicrobial Agents and Chemotherapy</i> , 35(5):801-807 (1991).	
↓	EK	Di Bisceglie, <i>et al.</i> , "Hepatocellular Carcinoma," NIH Conference, <i>Annals of Internal Medicine</i> , 108:390-401 (1988).	
	EL	Doong, <i>et al.</i> , "Inhibition of the Replication of Hepatitis B virus <i>in vitro</i> by 2',3'-Dideoxy-3'-Thiacytidine and Related Analogues," <i>Ntl. Acad. Sci. USA</i> , 88:8495-8499 (1991).	
Examiner:		Date Considered: 1/20/02	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			




Form PTO-1449		Docket No.	Application No.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		18085.105093 (EMU120CON)	09/879,854
		Applicant	
		Raymond F. Schinazi, <i>et al.</i>	
		Filing Date	Group/Art Unit
		June 12, 2001	1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	FA	Furman, <i>et al.</i> , "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of <i>cis</i> -5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl] Cytosine," <i>Antim. Agents and Chemo.</i> , 36(12):2686-2692 (1992).	
	FB	Ganem, "Animal Models of Hepatitis B Virus Infection," <i>Experimental Models in Antimicrobial Chemotherapy</i> , 2:259-273 (1986).	
	FC	Ganem, <i>et al.</i> , "The Molecular Biology of the Hepatitis B Viruses," <i>Ann. Rev. Biochem.</i> , 56:651-693 (1987).	
	FD	Gosselin, <i>et al.</i> , "Enantiomeric 2',3'-Deoxycytidine Derivatives are Potent Human Immunodeficiency Virus Inhibitors in Cell Cultures," <i>C.R. Acad. Sci. Paris Sci. Vie.</i> Inhibitory Effect of 2',3'-Didehydro-2',3'-Dideoxynucleosides on Infectivity, Cytopathic Effects, and Replication of Human Immunodeficiency Virus," 317:85-89 (1994).	
	FE	Hamamoto, <i>et al.</i> , <i>Antimicrob. Agents and Chemother.</i> , 31:907-910 (1987).	
	FF	Hoong, <i>et al.</i> , "Enzyme-Mediated Enantioselective Preparation of Pure Enantiomers of the Antiviral Agent 2'3'-Dideoxy-5-Fluoro-3'-Thiacytidine (FTC) and Related Compounds," <i>J. of Org. Chem.</i> , 57:5563-5565 (1992). (pg. 65 missing)	
	FG	Jeong, <i>et al.</i> , "Asymmetric Synthesis and Biological Evaluation of β -L-(2 <i>R</i> ,5 <i>S</i>)- and α -L-(2 <i>R</i> ,5 <i>R</i>)-1,3-Oxathiolane-Pyrimidine and -Purine Nucleosides as Potential Anti-HIV Agents," <i>J. Med. Chem.</i> , 36(2):181-195 (1993).	
	FH	Jeong, <i>et al.</i> , "An Efficient Synthesis of Enantiomerically Pure (+)-(2 <i>S</i> ,5 <i>R</i>)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine [(+)-BCH-189] from D-Galactose," <i>Tetrahedron Letters</i> , 33(5):595-598 (1992). (pp. 96 & 97 missing)	
	FI	Jones, <i>et al.</i> , "Minireview: nucleotide prodrugs," <i>Antiviral Research</i> , 27:1-17 (1995).	
	FJ	Jurovcik and Holy, "Metabolism of pyrimidine L-nucleosides," <i>Nucleic Acid Research</i> , 3(8):2143-2154 (1976)	
	FK	Kassianides, <i>et al.</i> , "Inhibition of Duck Hepatitis B Virus Replication by 2',3'-Dideoxycytidine," <i>Gastroenterology</i> , 97(5):1275-1280 (1989).	
	FL	Kim, <i>et al.</i> , "Potent Anti-HIV and Anti-HBV Activities of (-)-L- β -Dioxolane-C and (+)-L- β -Dioxolane-T and Their Asymmetric Syntheses," <i>Tetrahedron Letters</i> , 33(46):6899-6902 (1992)	
	FM	Kim, <i>et al.</i> , "1,3-Dioxolanyl-purine Nucleosides (2 <i>R</i> ,4 <i>R</i>) and (2 <i>R</i> ,4 <i>S</i>) with Selective Anti-HIV-1 Activity in Human Lymphocytes," <i>J. Med. Chem.</i> , 36(1):30-37 (1993)	
Examiner:		Date Considered: 1/20/02	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			



Form PTO-1449		Docket No:	Application No.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		18085.105093 (EMU120CON)	09/879,854
		Applicant:	
		Raymond F. Schinazi, <i>et al.</i>	
		Filing Date:	Group/Art. Unit:
		June 12, 2001	1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	GA	Kim, <i>et al.</i> , "L- β -(2S,4S)- and L- α -(2S,4R)-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships," <u>J. of Med. Chem.</u> , 36(5):519-528 (1993)	
	GB	Krenitsky, <i>et al.</i> , "3'-Amino-2'3'-Dideoxyribonucleosides of Some Pyrimidines: Synthesis and Biological Activities," <u>J. Med. Chem.</u> , 26(6) 891-895 (1983).	
	GC	Kukhanova, <i>et al.</i> , "L- and D-Enantiomers of 2',3'-Dideoxycytidine 5'-Triphosphate Analogs as Substrates for Human DNA Polymerases," <u>J. Bio. Chem.</u> , 270(39):23055-23059 (1995).	
	GD	Lee, <i>et al.</i> , "In Vitro and In Vivo Comparison of the Abilities of Purine and Pyrimidine 2',3'-Dideoxynucleosides To Inhibit Duck Hepadnavirus," <u>Antimicrobial Agents and Chemotherapy</u> , 33(3):336-339 (1989)	
	GE	Lin, <i>et al.</i> , "Potent and Selective In Vitro Activity of 3'-Deoxythymidin-2-Ene-(3'-Deoxy-2',3'-Didehydrothymidine) Against Human Immunodeficiency Virus," <u>Biochem. Pharm.</u> 36(17):2713-2718 (1987).	
	GF	Mahmoudian, <i>et al.</i> , "Enzymatic Production of Optically Pure (2'R- <i>cis</i>)-26;-deoxy-3'miacytidine (3TC,Lamivudine): A Potent Anti-HIV Agent," published by the Glaxo Group Research Ltd., <u>Enzyme Microb. Technol.</u> , Vol. 15:749-755 (1993)	
	GG	Mansuri, M.M., <i>et al.</i> , "Preparation of the Geometric Isomers of DDC, DDA, D4C, and D4T. As Potential AntiHIV Agents. .," <u>Bioorg. Med. Chem. Lett.</u> , 1:65-68 (1991). 1:1	
	GH	Matthes, <i>et al.</i> , "Potent Inhibition of Hepatitis B Virus Production in Vitro by Modified.Pyrimidine Xlycleosides . .," <u>Anti. Agents and Chemot.</u> , 34(10):1986-1990 (1990).	
	GI	Miller, <i>et al.</i> , "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses," <u>Proc. Natl. Acad. Sci. USA</u> , 83:2531-2535 (1986)	
	GJ	Mitsuya, <i>et al.</i> , "3'-Azido-3'-Deoxythymidine (BW A509U): An Antiviral Agent that Inhibits and Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus <i>in Vitro</i> ," <u>Proc. Natl. Acad. Sci. USA</u> , 82:7096-7100 (1985).	
GK	Mitsuya, <i>et al.</i> , "Rapid in Vitro Systems for Assessing Activity of Agents Against HTLV-III/LAV..." <u>AIDS: Modern Concepts and Therapeutic Challenges</u> , pp. 303-333, Marcel-Dekker, Inc., New York and Basel (1987).		
GL	Mitsuya, <i>et al.</i> , "Molecular Targets for AIDS Therapy," <u>Science</u> , 249:1533-1544 (1990).		
GM	Norbeck, <i>et al.</i> , "A New 2',3'-Dideoxynucleoside Prototype with <i>In Vitro</i> Activity Against HIV," <u>Tetrahedron Lett.</u> , pp. 6263-6266 (1989). 30:46		
Examiner:		Date Considered: 1/24/06	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			



Form PTO-1449		Docket No:	Application No.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		18085.105093 (EMU120CON)	09/879,854
		Applicant:	
		Raymond F. Schinazi, <i>et al.</i>	
		Filing Date:	Group Art Unit
		June 12, 2001	1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
HA	Norin, Chemical Abstracts, 108:146380, (1987).		
HB	Ohno, et al., <u>Chemical Abstracts</u> , 112:194612 "Chiral Synthons by Ester Hydrolysis Catalyzed by Pig Liver Esterase." (1989).		
HC	Okabe, et al., "Synthesis of the Dideoxynucleosides ddC and CNT from Glutamic Acid, Ribonolactone, and Pyrimidine Bases...", <u>J. Org. Chem.</u> , 53(20):4780-4786 (1988).		
HD	Pai, et al., "Inhibition of Hepatitis B Virus by a Novel L-Nucleoside, 2'-Fluoro-5-Methyl- β -L-Arabinofuranosyl...", <u>Antimicrobial Agents & Chemotherapy</u> , 40(2):380-386 (1996).		
HE	Richman, et al., "The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex...", <u>N. Eng. J. Med.</u> , 317(4):192-197 (1987). (pg. 194 missing)		
HF	Ryan, et al., "9- β -L-Ribofuranosyladenine ("L-Adenosine"), <u>Synthetic Procedures in Nucleic Acid Chemistry</u> , Vol. 1, pp. 163-167, Interscience Publishers, NY, NY (1968).		
HG	Satsumabayashi, et al., "The Synthesis of 1,3-Oxathiolan-5-one Derivatives," <u>Bulletin on Chem. Soc. Japan</u> , 45:913-915 (1972).		
HH	Schinazi, et al., "Pure Nucleoside Enantiomers of β -2',3'-Dideoxycytidine Analogs are Selective Inhibitors of Hepatitis B Virus <i>In Vitro</i> ," <u>Antimicrobial Agents and Chemotherapy</u> , 38(9):2172-2174 (1994).		
HI	Schinazi, et al., "Selective Inhibition of Human Immunodeficiency Viruses by Racemates and Enantiomers of <i>cis</i> -5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolan-5-y]] Cytosine," <u>Antim. Agents and Chemo.</u> , 36(11):2423-2431 (1992).		
HJ	Schinazi, et al., "Activities of the Four Optical Isomers of 2',3'-Dideoxy-3'-Thiacytidine (BCH-189) against Human Immunodeficiency Virus Type 1 in Human Lymphocytes," ..., <u>Antimic Agents & Chemo.</u> , 36(3):672-676 (1992). (pgs. 673 and 674 missing)		
HK	Schinazi, et al., "Rapid Communications: Substrate Specificity of <i>Escherichia Coli</i> , Thymidine Phosphorylase for Pyrimidine Nucleoside with an Anti-Human Immunodeficiency Virus Activity," <u>Bioch. Pharm.</u> , 44(2):199-204 (1992). (pgs. 200, 202 and 204 missing)		
HL	Schinazi, et al., "Insights into HIV Chemotherapy," <u>AIDS Research and Human Retroviruses</u> 8(6):963-990 (1992).		
HM	Schinazi, et al., "Pharmacokinetics and Metabolism of Racemic 2',3'-Dideoxy-5...", <u>Antimicrobial Agents and Chemotherapy</u> 36(11):2432-2438 (1992).		
HN	Schinazi, et al., <u>Antimicrob. Agents Chemother.</u> , "Comparison of Inhibitory Activities of Various Antiviral Agents against Particle-Driven and Recombinant Human Immunodeficiency Virus Type 1 Reverse Transcriptase." (1989). 33:1 pp. 115-117		
Examiner:		Date Considered: 11/20/06	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			



Form PTO-1449		Docket No.	Application No.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		18085.105093 (EMU120CON)	09/879,854
		Applicant:	
		Raymond F. Schinazi, et al.	
		Filing Date	Group/Art Unit
		June 12, 2001	1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
2	IA	Sells, et al., Production of Hepatitis B Virus Particles in Hep G2 Cells Transfected with Cloned Hepatitis B Virus DNA", "Pro. Natl. Acad. Sci. USA, 84:1005-1009 (1997).	
	IB	Soudeyys, et al., "Anti-Human Immunodeficiency Virus Type 1 Activity and Vitro Toxicity of 2'-Deoxy-3'-Thiacytidine....," <u>Antimicrobial Agents and Chemotherapy</u> , 35(7):1386-1390(1991). (pg. 1387 missing)	
	IC	St. Clair, et al., <u>Antimicrob. Agents Chemother.</u> , 3'-Azido-3'-Dexythyridine Triphosphate as an Inhibitor and Substrat of Parified Human Immunodeficiency virus Reverse Transcriptase," 31:1972 (1987). 31:12 pg. 1972-1977	
	ID	Sterzycki, et al., "Synthesis and Anti-HIV Activity of Several 2'-Fluoro-Containing Pyrimidine Nucleoside," <u>J. Med. Chem.</u> , 33(8):2150-2157 (1990)*	
	IE	Storer, et al., "The Resolution and Absolute Stereochemisty of the Enantiomers of <i>cis</i> -1-[2-(Hydromethyl)-1,3-Oxathiolan-5-yl]cytosine (BCH-189): Equipotent Anti-HIV Agents," <u>Nucleosides & Nucleotides</u> , 12(2):225-236 (1993).	
	IF	Su, et al., "Nucleosides. 136. Synthesis and Antiviral Effects and Several 1-(2-Deoxy-2-Fluoro- β -D-Arabinofuranosyl)-5-Alkyluracils. Some Structure- Activity Relationships," <u>J. Med. Chem.</u> , 29(1):151-154 (1986).	
	IG	Sureau, et al., "Production of Hepatitis B Virus by a Differentiated Human Hepatoma Cell Line after Transfection with Cloned Circular HBV DNA," <u>Cell</u> , 47:37-47 (1986)	
	IH	Tsurimoto, et al., "Stable Expression and Replication of Hepatitis B Virus Genome ...in an integrated state in a human hepatoma call line transfected with the cloned viral DNA," <u>Proc. Natl. Acad. Sci. USA</u> , 84:444-448 (1987).	
	II	Volk, Wesley A., Editor, "Hepatitis, "Essentials of Medical Microbiology, J.B. Lippincott Company, (Philadelphia/Toronto) 2 nd Ed., pp. 609-618 (1982).	
	IJ	Vorbrüggen, et al., "Nucleoside Synthesis with Trimethylsilyl/Triflate and Perchlorate as Catalysts," <u>Chem. Ber.</u> , 114:1234-1255 (1981).	
	IK	Watanabe, et al., <u>J. Med. Chem.</u> , 33:2145-2150. "Synthesis and Anti-HIV-2 Activity of 2'-"4"-Plyoro Analogues of Active Anti-AIDS Nucleosides 3-Acidoes deoxythymidine (AZT) and 2',3'-Didesxyaytidine (DDC)" (1990).	
	IL	Wilson, et al., The Synthesis and Anti-HIV Activity of Pyrimidine Dioxolanyl Nucleosides," <u>Bioorganic & Medicinal Chemistry Letters</u> , 3(2):169-174 (1993).	
	IM	Wilson, et al., "A General Method for Controlling Glycosylation Stereochemistry in the Synthesis of 2'-Deoxyribose Nucleosides," <u>Tetrahedron Lett</u> , 31(13):1815-1818 (1990).	
	IN	Yokota et al. "Comparative Activities of Several Nucleoside Analogs Against Duck Hepatitis B Virus In Vitro," Denivotues by Previously unrecognized Metabolic Pathways 2'-Deoxyuri" <u>Antimicrobial Agents and Chemotherapy</u> , 34(7):1326-1330 (1990).	
	IO	Zhu, et al., "Cellular Metabolism of 3'-Azido-2',3'-Dideoxyuridine with Formation of 5'-O-Diphosphohexose" <u>Molecular Pharmacology</u> , 38:929-938 (1990).	
Examiner:		Date Considered: 1/20/02	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			